Lofexidine

CHEMBL17860 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
259.1 g/mol
LogP
2.6
Phase
4

A central alpha-2 adrenergic agonist used to manage the physical symptoms of opioid withdrawal and as an adjunct in treating ADHD. It reduces the release of norepinephrine to ease symptoms like anxiety, agitation, sweating, and muscle aches.

Peso molecular

259,1300 g/mol

LogP

2,60

TPSA

33,60 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(Oc1c(Cl)cccc1Cl)C1=NCCN1

InChI

InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)

Molecular Formula

C11H12Cl2N2O

HBD / HBA

1 / 2

Enlaces Rotables

3

Átomos Pesados

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A central alpha-2 adrenergic agonist used to manage the physical symptoms of opioid withdrawal and as an adjunct in treating ADHD. It reduces the release of norepinephrine to ease symptoms like anxiety, agitation, sweating, and muscle aches.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Lofexidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL17860. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 30668. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.